Why the Familiar Box Still Feels Safer: Brand and Generic Medicines in UK Practice

It is one of the most familiar exchanges in a UK pharmacy. A patient collects a repeat prescription and is handed a box that looks nothing like the one they have taken for years. The name on the front is different, the tablet may be a different shape or colour, and the leaflet is unfamiliar. They ask the obvious question: is this actually the same medicine?

The answer is usually yes — the same active substance, the same strength, the same route into the body. Yet a bare ‘yes’ rarely settles the matter, because the doubt was never really about chemistry. It was about recognition. Understanding why that doubt arises, and what can honestly be said about it, is more useful than either dismissing it or indulging it.

One molecule, one licensing standard

In the UK, a medicine cannot be sold without a marketing authorisation. A generic product must demonstrate to the MHRA that it contains the same active substance, in the same amount and pharmaceutical form, as a product already authorised — the reference product. It must be manufactured to the same standards of good manufacturing practice, with inspections of the sites involved, and its labelling and patient information must meet the same requirements.

What a generic does not have to repeat is the original clinical trial programme, because the safety and efficacy of the molecule are already established. That is not a loophole; it is the deliberate design of the generic system, and it is why competition can bring prices down without each new entrant repeating a decade of research.

What bioequivalence actually measures

Before authorisation, a generic is normally compared with the reference product in healthy volunteers. Researchers measure how much of the drug reaches the bloodstream and how quickly, summarised as the area under the concentration-time curve and the peak concentration. The 90% confidence interval for these measures must normally fall within the accepted range of 80% to 125% of the reference product.

That band can look wide to a non-specialist, and it is fair to say so. It is a regulatory convention designed to accommodate normal variation in absorption between individuals and between batches, not a licence to be 20% weaker. For medicines where small differences in blood levels carry greater consequences — lithium, ciclosporin, tacrolimus, warfarin and the antiepileptic drugs are the standard examples — the requirements are tighter and prescribers may specify a particular manufacturer's product. Modified-release formulations and inhaled devices deserve separate caution, because the delivery system, not just the molecule, influences the dose that arrives where it is needed.

The differences patients can actually see

Excipients are the inactive ingredients: fillers, binders, coatings, colours, flavourings and preservatives. They can differ between products, and occasionally they matter. A patient with a diagnosed intolerance may need to check for lactose or particular colourings; some people prefer to avoid gelatin capsules or alcohol-containing liquids; sugar-free versions exist for good reason. Tablet size and shape vary too, which is a genuine issue for anyone with swallowing difficulties.

Packaging is the most visible difference and the least clinically significant, yet it carries disproportionate weight. The box is the part of the medicine a patient recognises. Change it and the brain registers a substitution, however well explained.

The cost argument, stated carefully

Generic competition has substantially reduced NHS spending on many long-established medicines, and those savings fund treatments elsewhere in a cash-limited system. That is a legitimate public interest argument for generic prescribing, and it is the reason most NHS prescriptions are written generically.

But cost alone is an incomplete case. If a patient quietly stops taking a medicine because they do not trust the new box, the saving is a false economy and the clinical risk is real. The argument for generic substitution is strongest when it is paired with an explanation, not when it is presented as a fait accompli.

Confidence and the nocebo effect

There is a body of research suggesting that people report more side effects after switching to a generic, even when the active ingredient and blood levels are comparable. The most plausible explanation is expectation: a change in appearance signals change in effect, and symptoms that would otherwise be ignored are attributed to the new product. This is not malingering. It is a well-documented feature of how people experience medicines.

For clinicians the practical lesson is that reporting matters. Suspected adverse reactions to any medicine, branded or generic, should be reported through the Yellow Card scheme. A pattern of reports across many patients is how genuine formulation problems are detected, and dismissing concerns as imagination discourages the very reporting that makes the system work.

What is worth saying at the counter

A pharmacist has perhaps two minutes, and several points earn their place in that time. Confirm that the active ingredient, strength and form are unchanged. Explain that the licence has been granted on the basis of comparative testing against the original. Ask directly whether the patient has any known reaction to ingredients such as lactose or specific colourings, and check the leaflet together if so. Invite them to report anything that feels different rather than stopping the medicine silently.

Where consistency genuinely matters — epilepsy, transplant medicines, anticoagulation, some modified-release products, inhalers and biological medicines such as biosimilars, which are not generics at all — say so plainly and explain the reason. Where it does not, say that too, without condescension.

The NHS could not function on branded prescribing alone, and patients are not being fobbed off when they receive a generic. But trust is built in the explanation, not in the box. A short, honest conversation at the counter does more for adherence than any amount of reassurance printed on a leaflet.